2014 ASCO ANNUAL MEETING
Promedior highlights favorable data on myelofibrosis therapy
By Michael Fitzhugh
Friday, May 30, 2014
Positive preliminary data from a phase II trial of Promedior Inc.'s experimental myelofibrosis therapy, PRM-151, showed the anti-fibrotic immunotherapy to be safe, well tolerated and effective in reducing symptoms of the disease. The small open-label, prospective study demonstrated improvements in bone marrow fibrosis, hemoglobin levels, platelet count, spleen volume and symptoms, painting a promising picture said Promedior president and CEO Suzanne Bruhn, a veteran of Dublin-based Shire plc. The Lexington, Mass.-based company is excited to have early evidence of PRM-151's ability to target the foundations of fibrosis and validation of its potential to treat and reverse fibrotic diseases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.